lbp-6 Antibody

What is LBP and what role does it play in immune responses?

LBP (Lipopolysaccharide binding protein) is a 58-62 kDa single-chain glycoprotein member of the BPI/LBP family within the BPI/PLUNC/PSP superfamily of lipid-binding proteins. This protein is secreted by multiple mammalian cell types, including hepatocytes, gingival keratinocytes, intestinal Paneth cells, and type II Greater alveolar cells . LBP functions as a class 1 acute phase reactant (APR) that is induced upon exposure to both IL-1 and IL-6, which appear when immune cells encounter pathogenic microbes . Following synthesis and release, LBP interacts with bacterial wall components, particularly lipopolysaccharide (LPS) from Gram-negative bacteria, playing a critical role in initiating and modulating immune responses to bacterial challenges . LBP's primary function is to bind LPS and facilitate its interaction with immune cell receptors, thereby helping to coordinate appropriate inflammatory responses.

What are the standard detection methods for LBP in research applications?

Several established methods are employed to detect LBP in research settings:

• Western Blot: This technique allows for size-based detection and semi-quantitative analysis of LBP protein. For optimal results, PVDF membranes probed with specific anti-LBP antibodies (such as AF6635 for mouse LBP or AF870 for human LBP) followed by appropriate HRP-conjugated secondary antibodies are commonly used . The specific band for LBP typically appears at approximately 65 kDa under reducing conditions.

• Enzyme-Linked Immunosorbent Assay (ELISA): Sandwich ELISA provides quantitative measurement of LBP in biological samples. The assay typically employs monoclonal antibodies against LBP for both capture and detection functions .

• Surface Plasmon Resonance (SPR): This technique can be used to analyze the binding kinetics between LBP and its ligands, such as LPS or membrane components . SPR allows real-time monitoring of biomolecular interactions without the need for labels.

• Cell-Based Functional Assays: These measure LBP activity through its effects on cellular responses, particularly TNF-α and IL-6 production by mononuclear cells in response to LPS stimulation .

What are the normal reference ranges for LBP in human biological samples?

Based on measurements from 20 normal individuals, the reference ranges for LBP concentrations are as follows:

These values provide important baseline reference points for researchers studying LBP in various physiological and pathological states . It is important to note that LBP levels may increase significantly during acute phase responses to infection or inflammation, making these ranges particularly valuable for determining abnormal elevations in research and clinical settings.

How does LBP interact with lipopolysaccharide, and what mechanisms govern this interaction?

The interaction between LBP and LPS involves complex molecular mechanisms that have been elucidated through various experimental approaches. Surface Plasmon Resonance (SPR) studies have demonstrated that LBP binds directly to LPS and can also interact with phospholipid membranes . The interaction dynamics depend on several factors:

• Binding Kinetics: SPR experiments reveal that LBP can bind to immobilized phosphatidylserine (PS) liposomes, forming a stable complex. When LPS is subsequently introduced, it can either bind to the liposome-bound LBP or form a tertiary complex with LBP and the liposome .

• Concentration-Dependent Effects: The molar ratio between LBP and LPS significantly influences the biological outcome of their interaction. At lower concentrations, LBP enhances LPS-induced cellular responses, while at higher concentrations or when pre-incubated with LPS, LBP can inhibit these responses .

• Conformational Changes: Evidence suggests that LBP undergoes conformational changes upon binding to LPS, which affects its subsequent interactions with cellular receptors and may determine whether it promotes or inhibits LPS-induced responses .

These mechanisms highlight LBP's dual role in both enhancing and inhibiting LPS-induced inflammatory responses, making it a critical regulator of immune responses to bacterial lipopolysaccharides.

What is the significance of autoantibodies against LBP in psychiatric disorders?

Recent research has uncovered a novel association between autoantibodies against LBP and psychiatric disorders. A study involving young adults with psychiatric diseases found significantly higher serum levels of anti-LBP antibodies compared to population-based controls (p = 5.248 × 10^-10) . The findings reveal several important associations:

• Distribution Patterns: The distribution of autism spectrum disorders (p = 2.0 × 10^-4) and hospital care for infections as adults (p = 0.036) differed between patient groups with varying levels of anti-LBP antibodies .

• Inflammatory Marker Correlations: Patients with high anti-LBP levels showed lower levels of several pro-inflammatory markers, including IL-1β, and the lowest serum LBP levels (p = 3.5 × 10^-5) .

• Functional Effects: Cell-based models demonstrated that anti-LBP antibodies could interfere with LBP signaling, reducing both IL-1β and IL-6 release from activated monocytes in response to LBP and LPS stimulation (p = 0.0001 and p = 0.02, respectively) .

These findings suggest that autoantibodies against LBP may influence TLR4-based immune responses, potentially affecting vulnerability to both infections and psychiatric disorders. This represents an emerging area of research at the intersection of immunology and psychiatry that merits further investigation.

How does the sequence of addition of LBP and LPS affect experimental outcomes in cellular assays?

The temporal relationship between LBP and LPS addition in experimental setups has been shown to significantly impact cellular responses. Research involving mononuclear cells (MNCs) has demonstrated:

• Sequential Addition: When LBP and LPS (at a fixed concentration of 1 ng/ml or approximately 400 pM) are added sequentially to serum-free MNCs, an increase in LPS-induced TNF-α release is observed with increasing amounts of LBP, regardless of the order of addition .

• Pre-incubation Effects: In contrast, when LBP and LPS are pre-incubated together (15 min, 37°C) before addition to MNCs, there is a significantly lower TNF-α production compared to conditions without additional LBP . This inhibitory effect becomes more pronounced at higher LBP:LPS molar ratios, with TNF-α levels comparable to unstimulated MNCs reached at a molar ratio of 10:1 .

• Concentration Dependence: The dual effect of LBP (enhancement versus inhibition of LPS activity) is concentration-dependent, with inhibition occurring at higher LBP:LPS ratios .

These findings highlight the importance of carefully controlling the timing, sequence, and relative concentrations of LBP and LPS in experimental designs. Researchers should specify these parameters in their protocols to ensure reproducibility and proper interpretation of results.

What are the recommended sample preparation protocols for LBP antibody-based assays?

Proper sample preparation is crucial for accurate LBP detection and quantification. Based on established protocols:

• For Western Blot Analysis:

  • Tissue lysates should be prepared under reducing conditions

  • Use of specialized immunoblot buffer groups (e.g., Immunoblot Buffer Group 1) is recommended for optimal results

  • Samples should be run on SDS-PAGE gels with appropriate molecular weight markers

• For Immunoassays (ELISA):

  • Serum and plasma samples typically require dilution (e.g., 200-fold in 1% MSD Blocker A Solution)

  • Prepare an 8-point standard curve using calibrator stock with appropriate dilution series (e.g., 7-fold dilutions in Diluent 15)

  • Include a zero calibrator blank using the appropriate diluent

• For Cell-Based Functional Assays:

  • Mononuclear cells should be isolated using density gradient centrifugation

  • Cells should be washed in serum-free medium and adjusted to appropriate concentration (e.g., 5 × 10^6 cells/ml)

  • Stimulation should be performed in serum-free conditions to avoid interference from serum LBP or other factors

• Sample Storage:

  • Store antibodies at temperatures recommended by manufacturers (typically -20 to -70°C as supplied)

  • For reconstituted antibodies, store at 2 to 8°C under sterile conditions for up to 1 month, or at -20 to -70°C for up to 6 months

  • Multiple freeze-thaw cycles should be avoided

How should researchers optimize Western blot conditions for LBP detection?

Optimizing Western blot conditions for LBP detection requires attention to several key parameters:

• Antibody Selection and Dilution:

  • Species-specific anti-LBP antibodies should be selected (e.g., AF6635 for mouse, AF870 for human)

  • Optimal antibody dilutions should be determined empirically for each application, with 1 μg/mL being a recommended starting point for affinity-purified antibodies

  • Appropriate HRP-conjugated secondary antibodies should be selected based on the host species of the primary antibody (e.g., HAF016 for sheep primary antibodies)

• Membrane and Transfer Conditions:

  • PVDF membranes are commonly used for LBP detection

  • Transfer conditions should be optimized for proteins in the 60-70 kDa range

• Detection System:

  • Enhanced chemiluminescence is commonly used, but fluorescence-based detection systems can provide better quantitative results

  • For cancer biomarker studies, comparison between cancer and non-cancer samples is facilitated by loading controls, such as colloidal gold staining for total protein

• Troubleshooting:

  • If multiple bands are observed, optimization of blocking conditions or antibody dilution may be necessary

  • Use of positive controls with known LBP expression is recommended to validate assay performance

What controls should be included when using LBP antibodies in research?

Proper experimental controls are essential for ensuring the validity and reliability of results when using LBP antibodies:

• Positive Controls:

  • Known LBP-expressing tissues (e.g., mouse ovary tissue for mouse LBP)

  • Recombinant LBP protein at known concentrations

  • Samples from conditions known to upregulate LBP (e.g., acute phase response)

• Negative Controls:

  • Isotype control antibodies to assess non-specific binding

  • LBP-deficient samples (if available) or samples with knockdown/knockout of LBP

  • For cell-based assays, unstimulated cells to establish baseline cytokine production

• Technical Controls:

  • Loading controls for Western blot (e.g., housekeeping proteins or total protein staining)

  • Standard curves using recombinant LBP for quantitative assays

  • Diluent-only samples as zero calibrator blanks

• Validation Controls:

  • Multiple antibodies targeting different epitopes to confirm specificity

  • Multiple detection methods to corroborate findings

  • Dose-response experiments to verify biological relevance

By incorporating these controls, researchers can increase confidence in their findings and address potential technical and biological variables that might influence their results.